Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease

Tony D’Urzo*, James F. Donohue, David Price, Marc Miravitlles, Edward Kerwin

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β<inf>2</inf> adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.

Original languageEnglish
Pages (from-to)519-532
Number of pages14
JournalExpert Review of Respiratory Medicine
Volume9
Issue number5
Early online date24 Aug 2015
DOIs
Publication statusPublished - 2015

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Muscarinic Antagonists
Muscarinic Receptors
Therapeutics
Adrenergic Agonists
Nebulizers and Vaporizers
Formoterol Fumarate
aclidinium bromide
Health Status
Safety

Keywords

  • aclidinium bromide
  • bronchodilation
  • chronic obstructive pulmonary disease
  • combination therapy
  • dyspnea
  • formoterol fumarate
  • long-acting muscarinic antagonist
  • long-acting β2-agonist
  • symptoms

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. / D’Urzo, Tony; Donohue, James F.; Price, David; Miravitlles, Marc; Kerwin, Edward.

In: Expert Review of Respiratory Medicine, Vol. 9, No. 5, 2015, p. 519-532.

Research output: Contribution to journalArticle

D’Urzo, Tony ; Donohue, James F. ; Price, David ; Miravitlles, Marc ; Kerwin, Edward. / Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. In: Expert Review of Respiratory Medicine. 2015 ; Vol. 9, No. 5. pp. 519-532.
@article{4c15d8bc68f745039a8b87451f405a85,
title = "Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease",
abstract = "Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2 adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.",
keywords = "aclidinium bromide, bronchodilation, chronic obstructive pulmonary disease, combination therapy, dyspnea, formoterol fumarate, long-acting muscarinic antagonist, long-acting β2-agonist, symptoms",
author = "Tony D’Urzo and Donohue, {James F.} and David Price and Marc Miravitlles and Edward Kerwin",
year = "2015",
doi = "10.1586/17476348.2015.1081065",
language = "English",
volume = "9",
pages = "519--532",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease

AU - D’Urzo, Tony

AU - Donohue, James F.

AU - Price, David

AU - Miravitlles, Marc

AU - Kerwin, Edward

PY - 2015

Y1 - 2015

N2 - Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2 adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.

AB - Inhaled bronchodilator therapy is a mainstay of treatment for chronic obstructive pulmonary disease (COPD). Despite the number and types of treatments available, the control of symptoms and exacerbations remains suboptimal, and adherence to, and persistence with, inhaled therapy is generally poor. Results from clinical studies suggest that dual bronchodilator therapy with long-acting muscarinic receptor antagonists (LAMAs) and long-acting β2 adrenergic receptor agonists (LABAs) may provide additional benefit over LAMA or LABA monotherapy without additive effects on safety and tolerability. Several combinations of a LAMA plus a LABA have recently become available in a single inhaler for maintenance therapy for adults with moderate-to-severe COPD, including aclidinium bromide/formoterol fumarate, glycopyrronium/indacaterol and umeclidinium/vilanterol. Here, we review clinical data demonstrating significant improvements in bronchodilation, 24-h symptoms, and health status with aclidinium/formoterol twice daily, and discuss how this treatment can be implemented in clinical practice as part of a patient-focused approach to disease control.

KW - aclidinium bromide

KW - bronchodilation

KW - chronic obstructive pulmonary disease

KW - combination therapy

KW - dyspnea

KW - formoterol fumarate

KW - long-acting muscarinic antagonist

KW - long-acting β2-agonist

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=84941352366&partnerID=8YFLogxK

U2 - 10.1586/17476348.2015.1081065

DO - 10.1586/17476348.2015.1081065

M3 - Article

AN - SCOPUS:84941352366

VL - 9

SP - 519

EP - 532

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 5

ER -